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Abstract
Background:  Oral anticoagulants like the coumarin derivatives are characterised by a particularly
narrow therapeutic range. Any interfering co-medication can pose a challenge to establishing a
stable anticoagulant dosage regimen and thus present a serious risk for the patient. Here we
describe two cases of patients on anticoagulant therapy that suggest possible drug interactions
between phenprocoumon and the proton pump inhibitor omeprazole.
Results:   I n  b o t h  p a t i e n t s ,  t h e  I n t e r n a t i o n a l  No r m a l i s e d  R a t i o  ( I NR )  i n c r e a s e d  b e y o n d  t h e
therapeutic  range  after  they  were  given  omeprazole  for  the  treatment  of  gastrointestinal
symptoms. The INR returned to therapeutic levels after the phenprocoumon dose was reduced
(Case 1) and omeprazole discontinued (Case 2).
Conclusions:  The increased  anticoagulant activity of phenprocoumon  observed  in the  two
described cases and the known interaction potential of omeprazole suggest that the clearance of
phenprocoumon may have been reduced due  to competitive  inhibition  of  its degradation  by
omeprazole. Drug interactions may be one of the reasons for the difficulties encountered with
some patients in establishing a stable anticoagulant therapy. Physicians should carefully review any
concurrently used medication and if possible opt for drugs with a low interaction potential.
Background
Oral anticoagulants like the coumarin derivatives are
characterised by a particularly narrow therapeutic range.
Concurrently taken drugs such as alcohol, barbiturates,
and anti-inflammatory agents potentially interact with
coumarin derivatives and can seriously affect anticoagu-
lant activity. Any interfering comedication can pose a
challenge to establishing a stable anticoagulant dosage
regimen and thus present a serious risk for the patient
[1,2]. Here we describe two cases of possible drug inter-
actions between phenprocoumon and the proton pump
inhibitor omeprazole, requiring adjustment of the anti-
coagulant dose.
Case 1
A 68-year-old woman (height: 160 cm; body weight: 60
kg) with a history of recurring tachyarrhythmia, hyper-
tension and severe hyperlipaemia was treated with phen-
procoumon (Marcumar, Roche) since December 1998.
After an initial phasing-in period of about 5 month, the
required dosage for maintaining the patient's Interna-
tional Normalised Ratio (INR) between 2.1 and 2.7 had
stabilised at 51/2 to 61/2 tablets of phenprocoumon (3
mg/tablet) per week. At this stage, the INR was deter-
mined every 3 to 4 weeks to monitor anticoagulation
therapy.
Concurrently the patient was treated with β -acetyldigox-
in (Novodigal 0.2: 1 ×  1/day), sotalol hydrochloride (So-
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talex 80: 2 ×  1/day), piretanide (Arelix mite: 1 ×  1/day),
hydrochlorothiazide (Esidrix: 1 ×  1/day), irbesartan
(Aprovel 150: 1 ×  1/day), potassium chloride (Rekawan:
1 ×  1/day), and simethicone (Enzym-Lefax: 3 ×  1/day).
On October 15th 1999, a gastroscopy was performed to
investigate the patient's persistent upper abdominal
complaints. This revealed the presence of a large hiatus
hernia as well as histological evidence of reflux esophag-
itis. After commencing (October 15th) treatment with
omeprazole (Antra MUPS 1 ×  20 mg/day), the patient's
INR increased from initially 2.15 (determined on Octo-
ber 6th) to 3.34 (November 3rd), although the phenpro-
coumon dosing regimen and all other medication had
been continued without changes. For the following
weeks, the phenprocoumon dose was therefore reduced
to 51/2 tablets per week, compared to 6 tablets per week
just prior to omeprazole treatment. At the next check-up
(November 17th), the INR had returned to 2.28, a value
well within the targeted range.
Case 2
The second case concerns a 72-year-old diabetic woman
with advanced arthropathy which had immobilised her
for a considerable period of time. Her condition led to a
bilateral pulmonary embolism which was scintigraphi-
cally confirmed on April 9th 1999. A thrombosis in her
left leg was phlebographically confirmed six days later
and on April 16th the patient was put on a loading sched-
ule of phenprocoumon commencing with 4 tablets on
day 1, 3 on day 2, 1 on day 3, and further as required. At
the same time, the patient was given omeprazole (1 ×  20
mg before bedtime) to treat a minimal antrum gastritis.
Other co-medications were enalapril (Xanef: 1 ×  1/day),
glyburide (Euglucon: 1 ×  1/day), and dipyrone (Novalgin:
3 ×  20 drops/day).
Before anticoagulation was initiated, the patient's INR
value was 1.02. On the third and fourth day of anticoag-
ulation therapy it had increased to 2.02 and 3.28, respec-
tively. Because the patient responded so strongly, she
received no further phenprocoumon during the follow-
ing days. However, surprisingly the INR value remained
at the high level throughout the following 9 days. It was
suspected that this unusually long persistence of antico-
agulant activity was caused by interference of omepra-
zole with the metabolism (and thus elimination) of
phenprocoumon. Consequently, omeprazole was discon-
tinued on April 29th. Four days later the INR value had
decreased to 1.5 and anticoagulation therapy with phen-
procoumon was successfully resumed using initially 51/2
tablets per week. By mid July, the required dose for
maintaining the INR within the therapeutic range had
stabilised at 3 to 31/2 tablets/week.
In December 1999, the patient had to undergo minor
surgery and, thus, phenprocoumon was withheld for
three weeks. Within 7 days the INR value had dropped to
below 1.5, and no problems were encountered when an-
ticoagulation therapy was resumed with a loading sched-
ule similar to the one used in April. This observation lent
further support to the notion that indeed omeprazole
may have been responsible for the problems with the an-
ticoagulation regimen encountered in April.
Discussion
In both patients the INR increased beyond the therapeu-
tic range in correlation with omeprazole treatment. In
case 1, the INR returned to therapeutic levels after reduc-
ing the dosage of phenprocoumon. In case 2, even after
phenprocoumon was discontinued the INR remained
above therapeutic levels and decreased only after ome-
prazole was also discontinued; when phenprocoumon
was subsequently resumed there were no difficulties in
adjusting this patient's INR to the desired level. Nor were
any such difficulties encountered at a later stage when
phenprocoumon was first withheld from the same pa-
tient in preparation for surgery and then subsequently
reintroduced with the usual loading schedule. In neither
case were any of the other co-medications adjusted.
Throughout the observation period both patients contin-
ued with the routine of their other co-medications. Col-
lectively, above observations suggest that our difficulties
in adjusting the anticoagulation level may be due to some
interference from omeprazole. Unfortunately, neither
phenprocoumon nor omeprazole levels were measured
in our two patients and on the basis of the available evi-
dence any suggestions about the possible mechanism(s)
of interference remain speculative.
Omeprazole is known for its high potential to interact
with other drugs [3,4]. One of the reasons is the relatively
high affinity of omeprazole for certain isoenzymes, or
CYP isoforms, of the cytochrome P450 enzyme system.
This system has a key function in hepatic oxidative drug
metabolism [5] including the degradation of coumarin
derivatives [6,7], and common metabolic pathways to-
gether with the limited metabolic capacity of the in-
volved CYP isoenzymes are the major reason why so
many drug-drug interactions occur.
However, based on currently available evidence, ome-
prazole and phenprocoumon do not seem to be metabo-
lised via the same CYP isoforms. Omeprazole is primarily
metabolised via CYP2C19 and to a lesser extent by
CYP3A4 [3,8], whereas phenprocoumon is metabolised
via CYP2C9 and possibly also other, as yet to be identi-
fied isoforms [9]. In vitro experiments with human liver
microsomes indicate that omeprazole can actually inhib-
it CYP2C9, but it can do so only at relatively high concen-BMC Gastroenterology (2001) 1:2 http://www.biomedcentral.com/1471-230X/1/2
trations [8]. This would seem to preclude any clinically
significant interaction of omeprazole and phenprocou-
mon at the metabolic level. However, CYP2C19 is poly-
morphically expressed, resulting in substantial
interindividual variation in the metabolic rate of drugs
eliminated via this isoform [3,4,8]. Some individuals are
deficient in CYP2C19 and consequently metabolise ome-
prazole via alternative but less efficient pathways. In
such slow metabolisers the serum concentration of ome-
prazole has been reported to reach levels that are on av-
erage fivefold higher [10,11], and the area under the
serum concentration versus time curve to be on average
tenfold [10] or even 20-fold [11] greater than in normal
rate metabolisers. At those concentration levels it is pos-
sible that omeprazole could effectively compete with
phenprocoumon for binding sites on CYP2C9, thus re-
sulting in competitive inhibition of phenprocoumon me-
tabolism. This would explain the increased anticoagulant
activity of phenprocoumon which was evident in the two
described cases during co-medication with omeprazole.
Unfortunately, we do not know the CYP2C19 genotype of
our two patients described here.
Similar cases, involving the coumarin derivatives aceno-
coumarol and warfarin, have been reported also by oth-
ers [[12–14]]. But systematic studies on the interaction
potential of omeprazole with coumarin derivatives in
slow versus normal rate metabolisers are still lacking.
Drug interactions may be one of the reasons for the diffi-
culties encountered with some patients in establishing a
stable anticoagulant therapy. Physicians should carefully
review any concurrently used medication and if possible
opt for drugs that are known to have a low interaction po-
tential.
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